Singapore's commitment to research, innovation, and enterprise (RIE) has positioned the nation as a global leader in science and technology, with the Agency for Science, Technology and Research (A*STAR) playing a pivotal role in this ecosystem. The recent transition from the RIE2025 plan to RIE2030 marks a new era of focused, impact-driven investments totaling S$37 billion over five years starting April 2026. This evolution builds on substantial achievements, emphasizing value creation in high-impact areas like semiconductors, healthy ageing, and sustainability.
The RIE framework, coordinated by the National Research Foundation (NRF), integrates public research institutes like A*STAR, universities such as the National University of Singapore (NUS) and Nanyang Technological University (NTU), and industry partners to translate discoveries into economic and societal benefits. Under RIE2025, Singapore strengthened its advanced manufacturing hub status, deepened capabilities in artificial intelligence (AI), additive manufacturing, and robotics, and anchored multinational corporations (MNCs) while uplifting small and medium enterprises (SMEs).
Evolution from RIE2025 to RIE2030
The RIE2025 plan, spanning 2021 to 2025 with S$25 billion, laid strong foundations across four domains: Manufacturing, Trade and Connectivity (MTC); Human Health and Potential (HHP); Urban Solutions and Sustainability (USS); and Smart Nation and Digital Economy (SNDE). It sustained R&D investment at about 1% of GDP, fostering collaborations that led to breakthroughs in semiconductors, precision medicine, and climate resilience.
RIE2030 intensifies this momentum with a 32% funding increase to S$37 billion, sharpening focus amid global challenges like geopolitical tensions, technological acceleration, and local priorities such as ageing and decarbonisation. Key shifts include large-scale RIE Flagships and Grand Challenges, mission-oriented programs, enhanced AI/data capabilities, and a vibrant deep tech ecosystem. A*STAR Chairman Chorh Chuan Tan noted, "RIE will become increasingly crucial to enhance our competitiveness, drive economic growth and help address national priorities."
This strategic pivot ensures discoveries not only advance knowledge but scale to real-world deployment, bridging the 'Valley of Death' through pilots, testbeds, and commercialization support.
A*STAR's Central Role in the RIE Ecosystem
As Singapore's lead public-sector R&D agency, A*STAR attracts top talent, leads in strategic fields, and bridges academia, industry, and government. It nurtures scientists, engineers, and innovators while fostering an innovation and enterprise (I&E) ecosystem for economic impact. In RIE2030, A*STAR will advance frontier and applied research in semiconductors, manufacturing, health, biotech, sustainability, and digital technologies, while recruiting talent across disciplines.
A*STAR's institutes, such as the Institute of Microelectronics (IME), Genome Institute of Singapore (GIS), and Institute of High Performance Computing (IHPC), drive cross-disciplinary efforts. Collaborations with universities amplify this: NUS launched a Master of Science in Semiconductor Technologies, and NTU partners on AI and quantum initiatives via platforms like the Singapore-HIT Alliance for Research and Enterprise (SHARE).
Biomedical Breakthroughs and Precision Health
During RIE2025, A*STAR's response to COVID-19 exemplified rapid impact. A*STAR IDL, SIgN, GIS, and IMCB advanced SARS-CoV-2 understanding, immunology, and vaccination insights, while IHPC modeled transmission for policy. The National Precision Medicine (NPM) program sequenced over 100,000 genomes, enabling personalized interventions.
Biomedtech grew 60% to 493 companies, raising US$3.2 billion. Case studies include SERI's contribution to Roche's Vabysmo (US$4 billion sales) and Mirxes' IPO at US$1 billion valuation. For RIE2030, NPM Phase III targets 400,000-450,000 participants, with Grand Challenges on healthy longevity focusing on brain and physical function.Details in the official RIE2030 factsheet.
Photo by Stocker LL on Unsplash
- NATi mRNA BioFoundry accelerated vaccine development.
- Lucence doubled revenue to US$6 million via liquid biopsy tech.
- GUSTO study informed maternal-child health policies.
Semiconductors: Leading the RIE Flagship
Singapore produces 10% of global chips and 20% of equipment, bolstered by A*STAR IME and IMRE. RIE2025 saw GlobalFoundries acquire A*STAR spin-off Advanced Micro Foundry (AMF). The Semiconductor RIE Flagship, led by A*STAR and Economic Development Board (EDB), targets advanced packaging, heterogeneous integration, and photonics. Initiatives like SHINE Centre and NCAIP foster university-industry ties, with NUS and SUTD contributing talent.
Outcomes include growing deep tech startups like MetaOptics and NexGen Wafer Systems, positioning Singapore as a resilient supply chain node. Tan emphasized, "A*STAR is making strong progress across several fronts."
| Semiconductor Milestone | Impact |
|---|---|
| AMF Spin-off Acquisition | GlobalFoundries Expansion |
| 30+ Years R&D | 10% Global Chip Production |
| NUS MSc Program | Talent Pipeline |
Urban Solutions and Sustainability Advances
RIE2025 delivered carbon-capturing concrete (57.5% emission cut), optimized vegetable seeds (+20% choy sum yield), and coastal defenses like jute beams. USS domain in RIE2030 accelerates decarbonisation (3 MtCO₂e reduction goal) and resilience against heat and sea-level rise. A*STAR's IHPC and IMRE support urban modeling and materials.
Collaborations with universities via CREATE and CFI Singapore drive food/water security, e.g., desalination plants and CEA innovations.
Talent Development and University Partnerships
Researcher density reached 12.9 per 1,000 workforce, with 87 highly cited researchers (5x since 2014). A*STAR scholarships retained 80%+ of 1,900 scholars; RSSS lured leaders like Prof. Aaron Thean. Universities benefit from IARP, GUSTO extensions, and PhD exchanges (SRAP). RIE2030 expands fellowships and clinician-scientists (155 from 57).
NUS, NTU, and SUTD host semiconductor programs and AI grand challenges (300+ projects, SEA-LION LLM).
Industry Collaborations and Commercialization Successes
Joint labs like Rolls-Royce/SAESL (500 jobs) and maritime tools exemplify partnerships. Platforms like DxD Hub, EDDC, and AISG bridge translation. Spin-offs and MNC anchors (Boehringer Ingelheim) drive growth.Chairman Tan on pathways to impact.
Photo by Planet Volumes on Unsplash
- Quantum: CQT ranks 6th globally.
- Cyber: MariOT testbed, CATOS deepfake detector.
- Aerospace: 10% global MRO.
Challenges, Strategic Shifts, and Future Outlook
Global disruptions demand agility; RIE2030 counters with focused investments and ecosystem synergy. Challenges like the Valley of Death are addressed via validation funding and testbeds. Tan envisions Singapore as a hub for Key Opinion Leaders, with vibrant I&E: "We need the best people to work together across institutions."
Success metrics blend KPIs with milestones, e.g., dementia biomarkers from discovery to market. Emerging sectors like space and bioeconomy, plus AI/quantum, promise growth. By 2030, expect scaled impacts in semiconductors (20% equipment), healthy longevity, and net-zero urban solutions, solidifying Singapore's innovation prowess.
